New vaccine combo aims to slow Alzheimer's by targeting tau tangles
NCT ID NCT07167966
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests a vaccine called AADvac1, which targets tau tangles in the brain, a hallmark of Alzheimer's. It will be given alone or with another drug (donanemab) to 450 adults aged 50-80 with very early Alzheimer's. The goal is to see if this approach can reduce tau buildup and slow disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco (UCSF), Memory and Aging Center
San Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking thousands of dementia cases reshape how we care for patients?
- PET scans probe link between brain inflammation and Alzheimer's damage
- Can sound waves soothe Dementia's emotional turmoil?
- Can a Low-Dose immune calmer slow Alzheimer's decline?
- A stumble before memory slips? study tests if falls predict Alzheimer's
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?